Generic drug development hinges on demonstrating pharmaceutical equivalence and bioequivalence to reference products, guided by BCS classification and regulatory frameworks. Key steps include physicochemical characterization, excipient compatibility testing, and optimized manufacturing processes (e.g., granulation, direct compression). Solubility enhancement techniques—micronization, solid dispersions, cyclodextrin complexes—address poorly soluble APIs, while permeability enhancers and super‑disintegrants support high‑solubility, low‑permeability compounds. Taste‑masking and patient‑centric forms like ODTs, suspensions, and capsules improve acceptability. Stability studies under ICH conditions ensure shelf life, informing protective packaging. Tailored formulation strategies for each API—from bedaquiline’s moisture‑sensitive coating to carvedilol’s multipart strength tablets—ensure robust, uniform, and clinically effective generics.

ProductTherapeutic CategoryDosage FormAvailable Strengths
Bedaquiline FumarateAnti‑TBFilm‑coated tablet20 mg (scored), 100 mg
BilastineAntihistamineTablet; ODT10 mg (paediatric), 20 mg
CarvedilolAnti‑HypertensiveFilm‑coated tablet3.125 mg, 6.25 mg, 12.5 mg, 25 mg
RivaroxabanAnti‑CoagulantTablet; oral suspension2.5 mg, 10 mg, 15 mg, 20 mg tablets; 1 mg/mL solution
VonoprazanPCAB (acid blocker)Film‑coated tablet10 mg, 20 mg
AmisulprideAnti‑PsychoticUncoated tablet; oral solution; injectionTablets: 50 mg, 100 mg, 200 mg, 400 mg; IV solution: 5 mg/2 mL
Metoclopramide HClAnti‑EmeticTablet; dispersible tablet; syrup; injectionTablets/dispersible: 5 mg, 10 mg; Syrup: 5 mg/5 mL; Injection: 5 mg/mL
Sodium PASAnti‑TBTablet500 mg
BrivaracetamAnticonvulsantTablet; oral solution; injectionTablets: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg; Oral soln: 10 mg/mL; Injection: 50 mg/5 mL
EthopabateVeterinary drug (coccidiostat)Powder premix for feed4–40 ppm in feed
SilodosinHypertension; BPHHard gelatin capsule4 mg, 8 mg
Carglumic AcidHyperammonemiaDispersible tablet for oral suspension200 mg/tablet
Oseltamivir PhosphateAntiviralHard gelatin capsule; powder for suspensionCapsules: 30 mg, 45 mg, 75 mg; Suspension: 6 mg/mL
DapagliflozinAnti‑diabeticFilm‑coated tablet5 mg, 10 mg
EmpagliflozinAnti‑diabeticFilm‑coated tablet10 mg, 25 mg
BumetanideEdemaTablet; injectable solutionTablets: 0.5 mg, 1 mg, 2 mg; Injection: 0.25 mg/mL

🔵 Under Development

ProductTherapeutic CategoryIntended Dosage FormLikely Strengths/Notes
DotinuradHyperuricemia, GoutTabletUnder Development
Mirogabalin BesylateGabapentinoid (neuropathic pain)TabletUnder Development
VibegronOveractive bladder (OAB)TabletUnder Development
ResmetiromNonalcoholic steatohepatitis (NASH)TabletUnder Development
Bempedoic Acid*HypercholesterolemiaTabletUnder Development
Ruxolitinib*MyelofibrosisTabletUnder Development
Tofacitinib*Rheumatoid arthritisTabletUnder Development

1. Principles of Generic and New Formulation Development

  1. Regulatory Framework & Bioequivalence
    • Generics must demonstrate pharmaceutical equivalence (same API, strength, dosage form) and bioequivalence (comparable rate and extent of absorption) to the reference product. Regulatory guidance (e.g., US FDA ANDA, EMA MRP/DCP) defines acceptable pharmacokinetic (PK) limits (typically 80–125% of reference AUC and Cₘₐₓ).
  2. Physicochemical Characterization
    • BCS Classification guides strategy:
      • Class I (high solubility/permeability) often straightforward immediate‑release.
      • Class II (low solubility/high permeability) requires solubility‐enhancement (micronization, solid dispersions, lipid solutions).
      • Class III (high solubility/low permeability) may need permeability enhancers.
      • Class IV (low solubility/permeability) are most challenging.
  3. Excipients Selection & Compatibility
    • Choose excipients for manufacturability, stability, and performance (e.g., fillers, binders, disintegrants, coatings). Conduct compatibility studies (DSC, FTIR) to avoid API‐excipient interactions.
  4. Release Profile Design
    • Immediate vs. controlled (extended, delayed, pulsatile) release tailored to therapeutic need. Technologies include matrix tablets, coated pellets, multiparticulates.
  5. Manufacturing Process Development
    • Process (wet/dry granulation, direct compression, hot‐melt extrusion) is optimized for content uniformity, hardness, friability, and dissolution. Scale‐up considers equipment and process parameters.
  6. Stability & Packaging
    • Long‑term and accelerated stability studies per ICH Q1A(R2) ensure shelf‐life; moisture, light, and oxygen sensitivity dictate packaging choice.

2. Product‑Specific Development Strategies

Bedaquiline Fumarate (Anti‑TB)

  • BCS Class II (poor solubility): micronization plus hydrophilic carriers (e.g., povidone) in a solid dispersion can boost dissolution.
  • Film‑coated tablet: coating protects from humidity (bedaquiline hygroscopic); score line aids dose flexibility.
  • Stability: ensure photostability and prevent fumarate salt conversion.

Bilastine (Antihistamine)

  • BCS Class III (high solubility, low permeability): focus on permeability enhancement (e.g., surfactants).
  • Orally disintegrating tablet (ODT): use super‑disintegrants (croscarmellose sodium) for rapid mouth‐dissolution, improving onset.
  • Taste‐masking: essential for paediatric 10 mg ODT.

Carvedilol (Anti‑Hypertensive)

  • BCS Class II: enhance dissolution via lipid‑based carriers or solid dispersions.
  • Multiple strengths (3.125 – 25 mg): maintain uniform content in low‐dose tablets by careful API blending and granule size control.
  • Film coating: improve swallowability and mask bitterness.

Rivaroxaban (Anti‑Coagulant)

  • High solubility at low pH: immediate‐release tablets use acidifying agents to boost solubility in less acidic GI.
  • Oral suspension: for paediatric or swallow‐difficulty patients; requires solubilizers (e.g., cyclodextrins) and pH control, plus microbial preservation.

Vonoprazan (PCAB)

  • Acid‑stable potassium competitive acid blocker: tablet core stabilized against moisture; enteric coating may not be needed but can be applied to target release in stomach.
  • Dose titration: 10 mg vs. 20 mg coatings differentiated by film thickness.

Amisulpride (Anti‑Psychotic)

  • BCS Class I: conventional tablets suffice; however low doses (50 mg) require content uniformity techniques (e.g., granular layering).
  • Parenteral solution: sterile filtration, isotonicity adjustment, pH stabilization, and preservative compatibility.

Metoclopramide HCl (Anti‑Emetic)

  • Multiple forms:
    • Dispersible tablets use effervescent excipients for rapid dispersion.
    • Syrup: flavoring plus viscosity agents.
    • Injection: preservative‐free, pH ~4–5 for stability, controlled infusion rate to minimize extrapyramidal effects.

Sodium PAS (Anti‑TB)

  • High dose (500 mg) tablets require large fill volume; often film‑coated to mask salty taste and protect from moisture.

Brivaracetam (Anticonvulsant)

  • Rapid absorption needed: immediate‐release tablets optimized for disintegration time < 15 min.
  • Oral solution/injectable: surfactants (e.g., polysorbate 80) for solubilization; pH and osmolarity matched to physiological.

Ethopabate (Veterinary Coccidiostat)

  • Feed premix: uniform distribution at low ppm levels; uses carriers (e.g., rice hulls) to ensure blending and stability during pelleting.

Silodosin (BPH/Hypertension)

  • BCS Class IV: solubility/permeability enhancers for oral bioavailability.
  • Capsule fill: API‐excipient granules blended for dose uniformity; capsules protect from light.

Carglumic Acid (Hyperammonemia)

  • Dispersible tablet: rapidly dissolves in small volumes for pediatric dosing; taste‐masking critical.

Oseltamivir Phosphate (Antiviral)

  • Prodrug: maintain moisture control to prevent hydrolysis.
  • Capsule vs. suspension: suspension uses sugar or sugar‐free syrups with preservatives; fluidity enhancers.

Dapagliflozin & Empagliflozin (Anti‑diabetic)

  • BCS Class III: immediate‑release tablets with minimal excipients; ensure rapid onset.
  • Low‑dose content uniformity: wet granulation to prevent segregation.

Bumetanide (Edema)

  • Low dose (0.5–2 mg) tablets: use pelletized granules or layering to ensure uniformity.
  • Injection: isotonic, preservative considerations, use of solubilizers for pH 9–10 formulation.

3. Key Challenges & Solutions

  • Low‑dose Uniformity: use of granulation, pelletization, or layering.
  • Solubility Enhancement: micronization, cyclodextrin complexes, solid dispersions, lipid carriers.
  • Taste & Swallowability: coatings, ODT technologies, flavor masking.
  • Patient‑centric Dosage Forms: dispersible tablets, suspensions, ODTs for paediatrics/geriatrics.
  • Stability: moisture‑protective coatings, desiccants, robust packaging.